查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1887158

豬疫苗市場規模、佔有率、成長及全球產業分析：依類型、應用和地區劃分的洞察與預測（2024-2032）

Porcine Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 請詢問到貨日

價格

豬隻疫苗市場成長因素

隨著全球對動物健康、食品安全和畜牧生產力的日益重視，豬疫苗市場持續擴張。根據本報告預測，該市場規模預計將在2024年達到11.8億美元，2025年達到12.3億美元。此外，受豬病發病率上升和全球豬肉需求成長的推動，預計到2032年，該市場將顯著增長至19.3億美元。北美地區在2024年佔了全球市場45.76%的佔有率，這反映了該地區成熟的疫苗接種實踐、強有力的監管支持以及對人畜共患病預防的廣泛認識。

豬疫苗在降低豬的疾病負擔方面發揮著至關重要的作用，它們透過刺激免疫反應而不引起疾病。這些疫苗採用源自病毒、細菌、毒素和寄生蟲的抗原配製而成，幫助養殖戶保護牲畜免受毀滅性傳染病的侵害。對動物性蛋白質需求的成長和商業養殖場飼養密度的提高增加了疾病傳播的風險，進一步推動了豬隻疫苗的使用。例如，2024年初，歐洲養豬場豬流感的盛行率達到了56.6%，凸顯了加強疫苗接種策略以保護牲畜健康和經濟穩定的必要性。

市場驅動因素

豬病發生率的上升仍然是市場成長最強勁的驅動因素之一。豬繁殖與呼吸綜合症（PRRS）、口蹄疫、豬瘟和豬細小病毒等疾病對豬的生產力構成重大威脅。由於豬繁殖與呼吸綜合症（PRRS）對繁殖性能和呼吸系統健康的影響，僅PRRS一項每年就給美國養豬業造成約5.6億美元的損失。全球豬肉消費量的成長進一步推動了對更健康豬群的需求。預計到2023年，全球豬肉產量將達到1.2467億噸，這將推動疫苗的普及，以預防疫情爆發並確保食品安全。

市場限制因子

儘管需求不斷增長，但由於發展中國家疫苗接種率低，市場面臨嚴峻的挑戰。獸醫基礎設施有限、小農戶意識薄弱以及經濟限制阻礙了疫苗的廣泛接種。根據聯合國糧農組織的數據，每年約有20%的反芻動物在低收入地區過早死亡，其中近一半的死亡是由可預防的傳染病造成的。這些地區疫苗接種的延遲限制了市場成長，並增加了疾病風險。

市場機會

政府主導的措施為市場擴張提供了巨大的機會。多個國家已啟動疫苗接種運動，以對抗豬病並增強豬群的抵抗力。例如，印度的畜牧健康和疾病管制計畫將於2024-2025年開展針對25萬頭豬的經典豬瘟（CSF）疫苗接種運動，這將推動對高品質疫苗的需求。預計到2032年，對疾病預防和宣傳計畫的投入增加將加速疫苗的普及。

市場挑戰

豬繁殖與呼吸綜合症病毒（PRRSV）和豬流感病毒（SIV）等病原體的快速基因突變使得開發長期普遍有效的疫苗變得困難。這些不斷演變的病毒株迫使生產商不斷更新疫苗配方。除了生物學挑戰外，嚴格的監管審批流程也會延遲產品上市並增加研發成本。對於計劃進行全球產品擴張的公司而言，應對各地區不同的法規仍然是一項重大挑戰。

市場趨勢

技術進步，特別是基因型特異性疫苗，正在塑造豬免疫的未來。這些疫苗基於病原體的基因譜設計，能夠提供更精準的標靶性和更強的免疫反應。 2024年10月，Seba公司基於PCV2d的疫苗Cirbloc M Hyo獲得歐洲批准，該疫苗旨在應對豬群中兩種最常見的呼吸道病原體。此類創新能夠改善豬群健康，減少經濟損失，並將基因型疫苗確立為2032年的關鍵成長趨勢。

區域展望

北美

在嚴格的監管標準、高豬肉消費量和先進的獸醫基礎設施的支撐下，預計北美市場將在2024年達到5.4億美元。美國仍然是主要貢獻者，這得益於其積極的研發計劃，包括開發針對非洲豬瘟 (ASF) 的新疫苗。

歐洲

歐洲在區域市場規模中排名第二，這主要得益於豬肉產量和疾病發生率的成長。在英國，預計 2024 年豬肉產量將增加 8.9%，凸顯了持續採取疾病預防措施的必要性。

亞太地區

亞太地區是成長最快的地區，這主要得益於中國、日本、越南和印度龐大的豬隻存欄量。旨在提高疫苗接種率的國家舉措，例如 NADCP 項目，將支持市場在 2032 年前的強勁成長。

拉丁美洲、中東和非洲

由於豬肉消費量的增長和動物健康計劃的擴展，預計這些地區將經歷緩慢但穩定的增長。預計到 2033 年，墨西哥人均豬肉消費量將達到 22.6 公斤，這將增加對疾病預防措施的需求。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：主要見解

  • 主要國家和地區豬病概覽（2024 年）
  • 主要國家及地區監理現況（2024 年）
  • 豬病疫苗概覽
  • 主要公司新產品發布
  • 主要產業趨勢（併購、合作等）
  • 新冠疫情的影響全球豬疫苗市場

第五章 全球豬隻疫苗市場分析、洞察與預測（2019-2032）

  • 市場分析、洞察與預測 - 依產品分類
    • 滅活​​疫苗
    • 減毒活疫苗
    • 重組疫苗
    • 其他
  • 市場分析、洞察與預測 - 依給藥途徑
    • 口服
    • 注射
  • 市場分析、洞察與預測 - 依銷售管道
    • 獸醫院
    • 獸醫診所
    • 藥局
    • 其他
  • 市場分析、洞察與預測 - 依地區
    • 北美美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美豬疫苗市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲豬疫苗市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 歐洲其他地區

第八章 亞太豬疫苗市場分析洞察與預測（2019-2032）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：拉丁美洲豬疫苗市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章：中東與非洲豬疫苗市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 海灣合作委員會
    • 南亞非洲
    • 中東和非洲其他地區

第十一章 競爭分析

  • 全球市佔率分析（2024 年）
  • 公司簡介
    • 禮來動保 (Elanco)
    • 喜普拉 (HIPRA)
    • 勃林格殷格翰國際有限公司 (Boehringer Ingelheim International GmbH)
    • 維克 (Virbac)
    • 默克公司 (Merck & Co., Inc.)
    • 碩騰服務有限公司 (Zoetis Services LLC)
    • 賽華 (Ceva)
    • 新健公司 (NEOGEN CORPORATION)
    • 赫斯特生物科學有限公司 (Hester Biosciences Limited)
Product Code: FBI112834

Growth Factors of porcine vaccines Market

The global porcine vaccines market continues to expand as animal health, food safety, and livestock productivity gain higher priority across the world. According to the report, the market was valued at USD 1.18 billion in 2024, is projected to reach USD 1.23 billion in 2025, and is expected to grow significantly to USD 1.93 billion by 2032, driven by rising disease outbreaks in swine populations and increasing global demand for pork. In 2024, North America accounted for 45.76% of the total market share, reflecting its well-established immunization practices, strong regulatory support, and widespread awareness of zoonotic disease prevention.

Porcine vaccines play an essential role in reducing disease burden in pigs by stimulating immune responses without causing illness. These vaccines are formulated using antigens derived from viruses, bacteria, toxins, or parasites, and help farmers protect herds from devastating infectious diseases. Rising demand for animal protein and increased stocking density in commercial farms elevate the risk of disease transmission, further boosting the adoption of porcine vaccines. For example, in early 2024, swine influenza prevalence in European pig herds reached 56.6%, highlighting the need for enhanced immunization strategies to safeguard livestock health and economic stability.

Market Drivers

The growing incidence of swine diseases remains one of the strongest drivers of market growth. Diseases such as Porcine Reproductive and Respiratory Syndrome (PRRS), foot-and-mouth disease, classical swine fever, and porcine parvovirus are major threats to swine productivity. PRRS alone costs the U.S. pork industry around USD 560 million annually, due to its effects on reproduction and respiratory health. Rising global pork consumption further intensifies the need for healthier herds. In 2023, global pig meat production reached 124.67 million tons, driving greater adoption of vaccines to prevent outbreaks and ensure food safety.

Market Restraints

Despite rising demand, the market faces significant challenges due to low immunization uptake in developing countries. Limited veterinary infrastructure, low awareness among small-scale farmers, and economic constraints impede widespread vaccination. According to FAO data, almost 20% of ruminants in low-income regions die prematurely each year, with nearly half of those deaths resulting from preventable infectious diseases. Slow vaccine adoption in these regions restricts market growth and increases disease risks.

Market Opportunities

Government-led initiatives represent a major opportunity for market expansion. Several countries are launching vaccination campaigns to control swine diseases and improve herd resilience. For example, India's Livestock Health & Disease Control Program initiated a 250,000-pig Classical Swine Fever (CSF) vaccination drive for 2024-25, bolstering demand for high-quality vaccines. Growing investments in disease prevention and educational outreach programs are expected to accelerate adoption through 2032.

Market Challenges

Rapid genetic mutations in pathogens like PRRSV and Swine Influenza Virus (SIV) create difficulties in developing long-lasting and universally effective vaccines. These evolving strains challenge manufacturers to constantly update vaccine formulations. Alongside biological challenges, stringent regulatory approvals further slow product launches and increase development costs. Navigating diverse regional regulations continues to be a significant hurdle for companies planning global product expansion.

Market Trends

Technological advancements, especially genotype-specific vaccines, are shaping the future of porcine immunization. These vaccines are engineered based on pathogen genetic profiles, offering improved targeting and stronger immune responses. In October 2024, Ceva secured European approval for Cirbloc M Hyo, a PCV2d-based vaccine designed to address two of the most prevalent respiratory pathogens in swine. Such innovations enhance herd health and reduce economic losses, establishing genotype vaccines as a key growth trend through 2032.

Regional Outlook

North America

North America recorded a market size of USD 0.54 billion in 2024, driven by strong regulatory standards, high pork consumption, and advanced veterinary infrastructure. The U.S. remains the dominant contributor, supported by active R&D programs, including development of new vaccines for African Swine Fever (ASF).

Europe

Europe forms the second-largest regional market, supported by increasing pork production and rising disease prevalence. In the U.K., pig meat production rose 8.9% in 2024, highlighting the need for consistent disease prevention practices.

Asia Pacific

Asia Pacific is the fastest-growing region, driven by large pig populations in China, Japan, Vietnam, and India. National initiatives such as the NADCP program aim to improve immunization rates, supporting strong market expansion through 2032.

Latin America & Middle East/Africa

These regions are experiencing slower but steady growth due to rising pork consumption and expanding animal health programs. In Mexico, pork consumption is expected to reach 22.6 kg per person by 2033, boosting demand for disease control measures.

Conclusion

The porcine vaccines market is positioned for strong long-term growth, increasing from USD 1.18 billion in 2024 to USD 1.23 billion in 2025, and projected to reach USD 1.93 billion by 2032. With rising disease threats, technological advancements, and global initiatives targeting livestock health, demand for effective porcine vaccines will continue accelerating worldwide.

Segmentation By Product

  • Inactivated
  • Live Attenuated
  • Recombinant
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Veterinary Hospitals
  • Veterinary Clinics
  • Pharmacies & Drug Stores
  • Others

By Region

  • North America (By Product, Route of Administration, Distribution Channel, Country/Sub-Region)
    • U.S.
    • Canada
  • Europe (By Product, Route of Administration, Distribution Channel, Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Product, Route of Administration, Distribution Channel, Country/Sub-Region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Product, Route of Administration, Distribution Channel, Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product, Route of Administration, Distribution Channel, Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Overview of Porcine Diseases by Key Countries, By Key Countries/ Region, 2024
  • 4.2. Regulatory Scenario by Key Countries/ Region, 2024
  • 4.3. Overview of Vaccination for Porcine Diseases
  • 4.4. New Product Launches, By Key Players
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.6. Impact of COVID-19 on the Global Porcine Vaccines Market

5. Global Porcine Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. Inactivated
    • 5.1.2. Live Attenuated
    • 5.1.3. Recombinant
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Veterinary Hospitals
    • 5.3.2. Veterinary Clinics
    • 5.3.3. Pharmacies & Drug Stores
    • 5.3.4. Others
  • 5.4. Market Analysis, Insights and Forecast - Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Porcine Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. Inactivated
    • 6.1.2. Live Attenuated
    • 6.1.3. Recombinant
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Veterinary Hospitals
    • 6.3.2. Veterinary Clinics
    • 6.3.3. Pharmacies & Drug Stores
    • 6.3.4. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Porcine Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. Inactivated
    • 7.1.2. Live Attenuated
    • 7.1.3. Recombinant
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Veterinary Hospitals
    • 7.3.2. Veterinary Clinics
    • 7.3.3. Pharmacies & Drug Stores
    • 7.3.4. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. Germany
    • 7.4.2. U.K.
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Porcine Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. Inactivated
    • 8.1.2. Live Attenuated
    • 8.1.3. Recombinant
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Veterinary Hospitals
    • 8.3.2. Veterinary Clinics
    • 8.3.3. Pharmacies & Drug Stores
    • 8.3.4. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Porcine Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. Inactivated
    • 9.1.2. Live Attenuated
    • 9.1.3. Recombinant
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Parenteral
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Veterinary Hospitals
    • 9.3.2. Veterinary Clinics
    • 9.3.3. Pharmacies & Drug Stores
    • 9.3.4. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Porcine Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. Inactivated
    • 10.1.2. Live Attenuated
    • 10.1.3. Recombinant
    • 10.1.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Parenteral
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Veterinary Hospitals
    • 10.3.2. Veterinary Clinics
    • 10.3.3. Pharmacies & Drug Stores
    • 10.3.4. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. Elanco
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. HIPRA
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Boehringer Ingelheim International GmbH
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Virbac
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Merck & Co., Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Zoetis Services LLC
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Ceva
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. NEOGEN CORPORATION
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Hester Biosciences Limited
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Porcine Vaccines Market Revenue (USD billion) Forecast, by Product, 2019-2032
  • Table 2: Global Porcine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 3: Global Porcine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 4: Global Porcine Vaccines Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 5: North America Porcine Vaccines Market Revenue (USD billion) Forecast, by Product, 2019-2032
  • Table 6: North America Porcine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 7: North America Porcine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 8: North America Porcine Vaccines Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 9: Europe Porcine Vaccines Market Revenue (USD billion) Forecast, by Product, 2019-2032
  • Table 10: Europe Porcine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 11: Europe Porcine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 12: Europe Porcine Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 13: Asia Pacific Porcine Vaccines Market Revenue (USD billion) Forecast, by Product, 2019-2032
  • Table 14: Asia Pacific Porcine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 15: Asia Pacific Porcine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 16: Asia Pacific Porcine Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 17: Latin America Porcine Vaccines Market Revenue (USD billion) Forecast, by Product, 2019-2032
  • Table 18: Latin America Porcine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 19: Latin America Porcine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 20: Latin America Porcine Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 21: Middle East & Africa Porcine Vaccines Market Revenue (USD billion) Forecast, by Product, 2019-2032
  • Table 22: Middle East & Africa Porcine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 23: Middle East & Africa Porcine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 24: Middle East & Africa Porcine Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Porcine Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Porcine Vaccines Market Value Share (%), by Product, 2024 & 2032
  • Figure 3: Global Porcine Vaccines Market Value Share (%), by Route of Administration, 2024 & 2032
  • Figure 4: Global Porcine Vaccines Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 5: Global Porcine Vaccines Market Value Share (%), by Region, 2024 & 2032
  • Figure 6: North America Porcine Vaccines Market Value (USD billion), by Product, 2024 & 2032
  • Figure 7: North America Porcine Vaccines Market Value Share (%), by Product, 2024
  • Figure 8: North America Porcine Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 9: North America Porcine Vaccines Market Value Share (%), by Route of Administration, 2024
  • Figure 10: North America Porcine Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 11: North America Porcine Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 12: North America Porcine Vaccines Market Value (USD billion), By Country, 2024 & 2032
  • Figure 13: North America Porcine Vaccines Market Value Share (%), By Country, 2024
  • Figure 14: Europe Porcine Vaccines Market Value (USD billion), by Product, 2024 & 2032
  • Figure 15: Europe Porcine Vaccines Market Value Share (%), by Product, 2024
  • Figure 16: Europe Porcine Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 17: Europe Porcine Vaccines Market Value Share (%), by Route of Administration, 2024
  • Figure 18: Europe Porcine Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 19: Europe Porcine Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 20: Europe Porcine Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 21: Europe Porcine Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 22: Asia Pacific Porcine Vaccines Market Value (USD billion), by Product, 2024 & 2032
  • Figure 23: Asia Pacific Porcine Vaccines Market Value Share (%), by Product, 2024
  • Figure 24: Asia Pacific Porcine Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 25: Asia Pacific Porcine Vaccines Market Value Share (%), by Route of Administration, 2024
  • Figure 26: Asia Pacific Porcine Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 27: Asia Pacific Porcine Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 28: Asia Pacific Porcine Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 29: Asia Pacific Porcine Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 30: Latin America Porcine Vaccines Market Value (USD billion), by Product, 2024 & 2032
  • Figure 31: Latin America Porcine Vaccines Market Value Share (%), by Product, 2024
  • Figure 32: Latin America Porcine Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 33: Latin America Porcine Vaccines Market Value Share (%), by Route of Administration, 2024
  • Figure 34: Latin America Porcine Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 35: Latin America Porcine Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 36: Latin America Porcine Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 37: Latin America Porcine Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 38: Middle East & Africa Porcine Vaccines Market Value (USD billion), by Product, 2024 & 2032
  • Figure 39: Middle East & Africa Porcine Vaccines Market Value Share (%), by Product, 2024
  • Figure 40: Middle East & Africa Porcine Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 41: Middle East & Africa Porcine Vaccines Market Value Share (%), by Route of Administration, 2024
  • Figure 42: Middle East & Africa Porcine Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 43: Middle East & Africa Porcine Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 44: Middle East & Africa Porcine Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 45: Middle East & Africa Porcine Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 46: Global Porcine Vaccines Market Share (%), By Company, 2024